Roche delays $4.3B Spark buyout — again — as FTC review drags on

The Roche/Spark deal is still happening. On time. It’s just going to take a little longer.

So says the Swiss giant, which has extended its tender offer for a second time. Withdrawing and refiling the Premerger Notification and Report Form gives the FTC more time to complete its regulatory review — a routine practice that was also cited as reason for delay three weeks ago.